Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi‐drug refractory patients: A case series of high efficacy and safety profile-Reference-Cited by-同舟云学术

Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi‐drug refractory patients: A case series of high efficacy and safety profile

Published:2021-01 Issue:1 Volume:34 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Polat Ekinci Algün¹^ORCID,Bölük Kübra Nursel¹,Babuna Kobaner Goncagül¹^ORCID

Affiliation:

1. Department of Dermatology and Venereology İstanbul Faculty of Medicine, İstanbul University İstanbul Turkey

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14704

Reference18 articles.

1. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis

2. Real‐world evidence of secukinumab in psoriasis treatment – a meta‐analysis of 43 studies

3. Secukinumab in multi-failure psoriatic patients: the last hope?

4. The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis

5. Erythrodermic psoriasis and secukinumab: Our clinical experience

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of secukinumab and acitretin for generalized pustular psoriasis: A case report and review of literature;Journal of International Medical Research;2024-04

2. How should we do in the selection and follow-up of systemic conventional treatments in psoriasis?;Exploration of Musculoskeletal Diseases;2023-12-05

3. Secukinumab attenuates neuroinflammation and neurobehavior defect via PKCβ/ERK/NF-κB pathway in a rat model of GMH;Experimental Neurology;2023-02

4. Biological treatment for erythrodermic psoriasis;Expert Opinion on Biological Therapy;2022-09-28

5. Vaccine‐induced erythrodermic psoriasis in a child successfully treated with secukinumab: A case report and brief literature review;Dermatologic Therapy;2022-07-14